Anti-EGFR antibody Cetuximab is used in the clinic for the treatment of head and neck cancers and colorectal cancers (https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125084s273lbl.pdf), while the VEGFR2 antagonist Ramucirumab is used in hepatocellular carcinomas and gastric cancers (https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125477s034lbl.pdf). This evidence concerns the gene EGFR and colorectal cancer.